Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization

Haematologica

Volumn 102, Issue 1, 2017, Pages 52-59

  Evers, Dorothea ^a,b   Zwaginga, Jaap Jan ^a,b   Tijmensen, Janneke ^a,b   Middelburg, Rutger A ^a,b   de Haas, Masja ^a,b,c   de Vooght, Karen M K ^d   van de Kerkhof, Daan ^e   Visser, Otto ^f   Péquériaux, Nathalie C V ^g   Hudig, Francisca ^h   van der Bom, Johanna G ^a,b  

^a SANQUIN RESEARCH   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CENTRAL LABORATORY   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e CATHARINA HOSPITAL   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g Jeroen Bosch Hospital s   (Netherlands)

^h HAGA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; THYMOCYTE ANTIBODY; ALLOANTIBODY; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOIMMUNIZATION; APLASTIC ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE CONTROL STUDY; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; CONTINUOUS WAVE LASER; CONTROLLED STUDY; ERYTHROCYTE COUNT; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); RISK FACTOR; ADVERSE EFFECTS; CLINICAL TRIAL; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; HEALTH SURVEY; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNIZATION; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; NETHERLANDS; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNIZATION; ISOANTIBODIES; MALE; MIDDLE AGED; NEOPLASMS; NETHERLANDS; POPULATION SURVEILLANCE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85008311441     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.152074     Document Type: Article

References (55)

1. TRIP Hemovigilance report 2014. Available at: https://www.tripnet.nl/pages/nl/documents/TRIP2014Hemovigilantie.pdf.
2. SHOT-report 2014. Available at: http://www.shotuk.org/shot reports/report-summary-supplement-2014.
3. CBO Blood Transfusion Guideline 2011. English version accessible at: http://www.sanquin.nl/repository/documenten/en/prod-en-dienst/287294/bloodtransfusion-guideline.pdf.
4. Handbook of Transfusion Medicine, United Kingdom Blood Services, 5th edition, 2013. Available at: http://www.transfusionguidelines.org.uk/transfusion-handbook.
5. Evers D, Middelburg RA, de Haas M, et al. Red-blood-cell alloimmunisation in relation to antigens' exposure and their immunogenicity: a cohort study. Lancet Haematol. 2016;3(6):e284-292.
6. Bauer MP, Wiersum-Osselton J, Schipperus M, Vandenbroucke JP, Briet E. Clinical predictors of alloimmunization after red blood cell transfusion. Transfusion. 2007; 47(11):2066-2071.
7. Fasano RM, Booth GS, Miles M, et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol. 2015; 168(2):291-300.
8. Zalpuri S, Evers D, Zwaginga JJ, et al. Immunosuppressants and alloimmunization against red blood cell transfusions. Transfusion. 2014;54(8):1981-1987.
9. Arriaga F, Bonanad S, Larrea L, et al. Immunohematologic study in 112 patients with myelodysplastic syndromes: 10-year analysis. Sangre (Barc). 1995; 40(3):177-180.
10. Schonewille H, Haak HL, van Zijl AM. Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion. 1999;39(7):763-771.
11. Stiegler G, Sperr W, Lorber C, Fabrizii V, Hocker P, Panzer S. Red cell antibodies in frequently transfused patients with myelodysplastic syndrome. Ann Hematol. 2001;80(6):330-333.
12. Novaretti MC, Sopelete CR, Velloso ER, Rosa MF, Dorlhiac-Llacer PE, Chamone DA. Immunohematological findings in myelodysplastic syndrome. Acta Haematol. 2001;105(1):1-6.
13. Sanz C, Nomdedeu M, Belkaid M, Martinez I, Nomdedeu B, Pereira A. Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Transfusion. 2013;53(4):710-715.
14. Zalpuri S, Zwaginga JJ, van der Bom JG. Risk Factors for Alloimmunisation after red blood Cell Transfusions (R-FACT): a case cohort study. BMJ Open. 2012;2:e001150.
15. Evers D, van der Bom JG, Tijmensen J, et al. Red cell alloimmunisation in patients with different types of infections. Br J Haematol. 2016 Aug 18 [Epub ahead of print].
16. Rothman Kenneth J. Modern Epidemiology. Philadelphia, Lippincott Williams & Wilkins; 2008.
17. Alvarnas JC, Brown PA, Aoun P, et al. Acute lymphoblastic leukemia. J Natl Compr Canc Netw. 2012;10(7):858-914.
18. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649.
19. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-425.
20. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
21. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12):5446-5456.
22. WHO Collaborating Centre for Drug Statistics Methodology, Anatomic Therapeutic Chemical index 2016. Available at: http://www.whocc. no/atc_ddd_index.
23. Knol MJ, Vandenbroucke JP, Scott P, Egger M. What do case-control studies estimate? Survey of methods and assumptions in published case-control research. Am J Epidemiol. 2008;168(9):1073-1081.
24. Miettinen O. Estimability and estimation in case-referent studies. Am J Epidemiol. 1976;103(2):226-235.
25. Ferraro C, Quemeneur L, Prigent AF, Taverne C, Revillard JP, Bonnefoy-Berard N. Anthracyclines trigger apoptosis of both G0-G1 and cycling peripheral blood lymphocytes and induce massive deletion of mature T and B cells. Cancer Res. 2000; 60(7):1901-1907.
26. Gafter-Gvili A, Polliack A. Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leuk Lymphoma. 2016; 57(3):512-519-8.
27. Mackall CL, Fleisher TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 1994;84(7):2221-2228.
28. Tolaney SM, Najita J, Winer EP, Burstein HJ. Lymphopenia associated with adjuvant anthracycline/ taxane regimens. Clin Breast Cancer. 2008;8(4):352-356.
29. Remberger M, Sundberg B. Rabbitimmunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. Haematologica. 2005; 90(7):931-938.
30. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21(7):1387-1394.
31. Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation. 2005; 79(11):1507-1515.
32. Bedognetti D, Zoppoli G, Massucco C, et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. J Immunol. 2011;186(10):6044-6055.
33. Cha Z, Li C, Zang Y, et al. Adaptive B cell responses in rituximab-treated diffuse large B cell lymphoma patients during complete remission. Tumour Biol. 2015;37(1):829-835.
34. van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood. 2002;100(6):2257-2259.
35. Yri OE, Torfoss D, Hungnes O, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood. 2011;118(26):6769-6771.
36. Asfour M, Narvios A, Lichtiger B. Transfusion of RhD-incompatible blood components in RhD-negative blood marrow transplant recipients. MedGenMed. 2004; 6(3):22.
37. Cid J, Lozano M, Fernandez-Aviles F, et al. Anti-D alloimmunization after D-mismatched allogeneic hematopoietic stem cell transplantation in patients with hematologic diseases. Transfusion. 2006;46(2):169-173.
38. Mijovic A. Alloimmunization to RhD antigen in RhD-incompatible haemopoietic cell transplants with non-myeloablative conditioning. Vox Sang. 2002;83(4):358-362.
39. Booth C, Lawson S, Veys P. The current role of T cell depletion in paediatric stem cell transplantation. Br J Haematol. 2013; 162(2):177-190.
40. Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med. 1995; 332(3):143-149.
41. Mackall CL, Stein D, Fleisher TA, et al. Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults. Blood. 2000;96(2):754-762.
42. Oshrine BR, Li Y, Teachey DT, Heimall J, Barrett DM, Bunin N. Immunologic recovery in children after alternative donor allogeneic transplantation for hematologic malignancies: comparison of recipients of partially T cell-depleted peripheral blood stem cells and umbilical cord blood. Biol Blood Marrow Transplant. 2013;19(11): 1581-1589.
43. Storek J, Witherspoon RP, Storb R. T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant. 1995;16(3):413-425.
44. Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood. 2001;97(11):3380-3389.
45. Korholz D, Kunst D, Hempel L, et al. Humoral immunodeficiency in patients after bone marrow transplantation. Bone Marrow Transplant. 1996;18(6):1123-1130.
46. Storek J, Witherspoon RP, Storb R. Reconstitution of membrane IgD- (mIgD-) B cells after marrow transplantation lags behind the reconstitution of mIgD+ B cells. Blood. 1997;89(1):350-351.
47. Chow MT, Moller A, Smyth MJ. Inflammation and immune surveillance in cancer. Semin Cancer Biol. 2012;22(1):23-32.
48. Meirow Y, Kanterman J, Baniyash M. Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate. Front Immunol. 2015;6:523.
49. Upadhyay R, Hammerich L, Peng P, Brown B, Merad M, Brody JD. Lymphoma: immune evasion strategies. Cancers. 2015; 7(2):736-762.
50. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6(4):295-307.
51. Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126(5):573-581.
52. Hodgson K, Ferrer G, Pereira A, Moreno C, Montserrat E. Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment. Br J Haematol. 2011; 154(1):14-22.
53. Visco C, Barcellini W, Maura F, Neri A, Cortelezzi A, Rodeghiero F. Autoimmune cytopenias in chronic lymphocytic leukemia. Am J Hematol. 2014; 89(11):1055-1062.
54. Sinisalo M, Aittoniemi J, Kayhty H, Vilpo J. Vaccination against infections in chronic lymphocytic leukemia. Leuk Lymphoma. 2003;44(4):649-652.
55. Middelburg RA, Wiersum-Osselton JC, van de Watering LM, van der Bom JG. Observational etiologic research: part 3- case-control studies: it's all about the source population. Transfusion. 2014; 54(1):12-16.